Vanguard Global Advisers’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$258K Buy
20,122
+4,390
+28% +$35.8K ﹤0.01% 2374
2026
Q2
$156K Hold
15,732
– – ﹤0.01% 2598
2026
Q1
$96.4K Buy
+15,732
New +$131K ﹤0.01% 2745

Other funds holding DNA

Vanguard Global Advisers's DNA Position: Q3 2026 in Review

Vanguard Global Advisers increased its Ginkgo Bioworks (DNA) stake by 28% in Q3 2026, buying an estimated $35.8K and bringing the position to 20,122 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #2374.

Vanguard Global Advisers first reported a position in DNA in Q1 2026 and has held it in 3 quarters since. 185 funds tracked by Wall St. Rank hold DNA as of Q3 2026.

  • Vanguard Global Advisers held 20,122 shares of Ginkgo Bioworks worth $258K as of Q3 2026.
  • Vanguard Global Advisers bought 4,390 Ginkgo Bioworks shares in Q3 2026, an estimated $35.8K.
  • Ginkgo Bioworks made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2374 holding.
  • Vanguard Global Advisers first reported a position in Ginkgo Bioworks in Q1 2026 and has held it in 3 quarters since.
  • 185 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.